drugset / Trial / NCT00937352
A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
Phase 3
Terminated
896 enrolled
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Pfizer · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the long-term safety and tolerability of Bapineuzumab (AAB-001, ELN115727) in subjects with Alzheimer's disease who participated in study ELN115727-301 or study ELN115727-302.
Timeline
- Start
- 2009-07
- Primary completion
- 2012-09
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | bapineuzumab | Monoclonal antibody | 0.5 mg/kg | Intravenous |
| Comparator | bapineuzumab | Monoclonal antibody | 1 mg/kg | Intravenous |